Recent advances in the development of bispecific antibodies.

Author: Jintong YE ¹ ; Songdong MENG ² ; Xiaodong ZHU ¹
Author Information

1. Beijing Combio Pharmaceutical Co., Ltd, Beijing 101111, China.
2. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Publication Type:Journal Article
Keywords: antitumor drug; bispecific antibodies; therapeutic drugs
From: Chinese Journal of Biotechnology 2020;36(1):33-43
CountryChina
Language:Chinese
Abstract: Bispecific antibody (BsAbs) are antibodies (Abs) containing two different antigen-binding sites in one molecule. In the last decade, three BsAbs drugs have been approved for therapeutic use. Meanwhile there are a number of BsAbs in preclinical or clinical studies. In this review, we describe BsAb design, discovery, mechanism of action, and the recent research progress in developing BsAbs.